Summary of Celldex Therapeutics FY Conference Call Company Overview - **Company**: Celldex Therapeutics (NasdaqCM:CLDX) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 04, 2026 Key Points Industry and Product Development - **Ongoing Studies**: Enrollment completion in the CSU and EMBARQ programs, and initiation of the phase 3 CIndU study [7][9] - **Excitement Around Drug**: Increased enthusiasm for the drug due to recent approvals of competitors like Remy and Dupixent [14][16] - **Study Powering**: Studies are 90% powered to detect a 10-point difference in Urticaria Activity Score 7 compared to placebo, applicable to both overall and refractory subsets [17][19] Clinical Data and Efficacy - **Phase 2 Study Results**: 76-week follow-up data showed a complete response rate of 41%, with 51% at 12 weeks and 71% at 52 weeks, indicating rapid and deepening responses [39] - **Omalizumab Refractory Population**: No approved treatments have shown statistically significant efficacy in this group, highlighting a market opportunity for Celldex [40] - **Comparison with Competitors**: Remy has not shown significant differences in the omalizumab-experienced population [42] Market Strategy and Positioning - **Market Entry Points**: Two potential entry points identified: frontline therapy for severe CSU and as a second-line option after existing therapies [89][91] - **Market Growth Potential**: Anticipation of significant market growth with the introduction of Repzido and Dupixent, which have historically been underdiagnosed [92] Pricing Strategy - **Pricing Considerations**: Currently evaluating pricing strategies, aiming for a premium compared to Dupixent, Olumiant, and Rinvoq [78] Future Studies and Trials - **Phase 2 Trials**: Completed enrollment for prurigo nodularis (PN) study with 140 patients, focusing on itch and skin clearance as primary endpoints [146][148] - **Atopic Dermatitis Study**: Similar design to PN study, with data expected later in the year [180][186] Regulatory and Safety Monitoring - **Adverse Event Monitoring**: Patients monitored monthly for neutropenia and other adverse events, with no significant association with infections noted [80] - **Sperm Study**: Ongoing study expected to read out in time for BLA filing, focusing on the impact of barzolvolimab on sperm count and hormone levels [82][84] Competitive Landscape - **Market Dynamics**: Increased competition expected to enhance diagnosis rates and treatment options in the CSU and CIndU markets [134][137] - **Differentiation Strategy**: Emphasis on rapid relief of itch and skin clearance as key differentiators in treatment efficacy [148] Conclusion - **Outlook**: An action-packed year ahead with multiple studies and potential market entries, positioning Celldex Therapeutics favorably in the competitive landscape of allergy and dermatology treatments [224][226]

Core Thesis - Celldex Therapeutics, Inc. (CLDX) is positioned as a promising biotech investment for 2026, driven by its advancing immunology pipeline and positive clinical data [3][7]. Pipeline and Product Development - The company has initiated a second Phase III trial for its lead compound, barzolvolimab ("barzo"), targeting chronic inducible urticaria (CIndU), which follows a successful Phase III design for chronic spontaneous urticaria (CSU) [3][4]. - Barzo is described as a "pipeline in a drug," with the potential to target multiple mast cell diseases and achieve premium pricing, with management suggesting that its durable efficacy could support reimbursement comparable to Dupixent's $60,000 annual cost [4][5]. Market Expansion and Indications - Beyond CSU and CIndU, Celldex is preparing to expand into food allergies, leveraging market traction from Novartis' Xolair, and addressing Xolair-refractory patients, enhancing barzo's blockbuster potential [5][6]. - Additional indications for barzo include prurigo nodularis, atopic dermatitis, and chronic urticaria, which further solidify its long-term growth prospects [5]. Additional Products - The company is also developing a second mast cell-targeting monoclonal antibody, CDX-622, which shows promising biological activity and aims to target non-overlapping mast cell populations [6]. Investment Potential - With ongoing pipeline progress, clinical milestones, and the potential for premium pricing, CLDX is seen as an attractive investment opportunity, offering both near-term data readouts and long-term growth potential across multiple indications [7].

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, representing a major shift in the global economy driven by AI innovation [2] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is believed to be redefining work, learning, and creativity, attracting significant interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a major technological advancement with the potential for substantial social benefits [8] Market Trends - The AI ecosystem is expected to reshape business, government, and consumer operations globally, indicating a shift in market dynamics [2] - The investment landscape is becoming increasingly competitive, with major players like Tesla, Nvidia, Alphabet, and Microsoft being closely watched, while a smaller company is suggested to hold greater potential [6]

Core Viewpoint - Celldex Therapeutics, Inc. is facing significant financial challenges despite advancing in clinical trials for chronic spontaneous urticaria and other conditions [1][2]. Financial Performance - The company reported an earnings per share (EPS) of -$1.22, missing the estimated EPS of -$1.01 [2]. - Actual revenue was $121,000, significantly below the estimated $1.39 million [1][2]. - The price-to-sales ratio stands at 296.30, indicating a high premium paid by investors for each dollar of sales [2]. - The enterprise value to sales ratio is 188.14, further highlighting the high valuation relative to sales [2]. - The negative price-to-earnings (P/E) ratio is -9.12, and the negative earnings yield is -10.97%, reflecting profitability challenges [4]. Clinical Development - Enrollment in Phase 3 studies for chronic spontaneous urticaria has been completed, with topline data expected in Q4 2026 [3]. - Additional Phase 3 studies for cold urticaria and symptomatic dermographism are actively enrolling participants [3]. Financial Health - The company has a low debt-to-equity ratio of 0.0044, indicating minimal reliance on debt [4]. - A strong current ratio of 13.01 suggests robust liquidity, allowing the company to effectively cover short-term liabilities [4].

Clinical Development - Barzolvolimab (CDX-0159) has completed enrollment in Phase 3 studies for Chronic Spontaneous Urticaria (CSU), with topline data expected in Q4 2026; a Phase 2 study achieved primary efficacy endpoint with statistically significant mean change from baseline to Week 12 [353]. - In the Phase 2 study for CSU, over 40% of patients receiving 150 mg Q4W of barzolvolimab experienced a profound, sustained complete response at 76 weeks post-treatment [353]. - The company initiated a Phase 3 study in Cold Urticaria and Symptomatic Dermographism in December 2025, with enrollment ongoing; a Phase 2 study achieved primary efficacy endpoint [353]. - A Phase 2 study in Prurigo Nodularis (PN) was initiated in April 2024, with enrollment completed in December 2025; topline data is expected in summer 2026 [353]. - The next generation bispecific antibody platform, CDX-622, targets chronic inflammation pathways and has completed enrollment in a Phase 1a dose-escalation study [353]. - Two Phase 3 studies of barzolvolimab in Chronic Spontaneous Urticaria (CSU) initiated in July 2024, enrolling approximately 1,939 patients across 43 countries [386]. - The Phase 2 study included 196 patients across 85 sites, evaluating multiple dosing regimens of barzolvolimab for CIndU, with a primary endpoint of negative provocation test at Week 12 [395]. - The ongoing Phase 2 study in Prurigo Nodularis includes approximately 120 patients, with topline data expected in summer 2026 [410]. - The Phase 2 study in Atopic Dermatitis was initiated in December 2024, targeting a condition affecting up to 20% of the U.S. population [411]. - The Phase 2 study of barzolvolimab for moderate to severe atopic dermatitis (AD) involves approximately 120 patients, with topline data expected in late 2026 [415]. - Development in eosinophilic esophagitis (EoE) was discontinued after the Phase 2 study showed no improvement in symptoms despite achieving the primary endpoint of mast cell depletion [416]. Financial Performance - The company incurred an aggregate of $662.2 million in research and development expenses over the past five years, with $245.1 million in R&D expenses for the year ended December 31, 2025 [363]. - Total revenues for the year ended December 31, 2025, decreased by $5.475 million (78%) to $1.545 million compared to $7.020 million in 2024 [440]. - Research and development expenses increased by $81.524 million (50%) to $245.074 million for the year ended December 31, 2025, primarily due to expenses related to barzolvolimab [445]. - The net loss for the year ended December 31, 2025, increased by $100.894 million (64%) to $258.757 million compared to $157.863 million in 2024 [441]. - Contracts and grants revenue decreased by $5.559 million (79%) to $1.448 million for the year ended December 31, 2025, primarily due to reduced services performed under agreements with Rockefeller University [442]. - Product development expenses rose by $70.492 million (78%) to $161.096 million for the year ended December 31, 2025, driven by increased clinical trial and contract manufacturing costs for barzolvolimab [448]. - General and administrative expenses increased by $5.290 million (14%) to $43.838 million for the year ended December 31, 2025, due to higher employee headcount and commercial planning expenses [449]. - Investment and other income, net, decreased by $8.605 million (23%) to $28.610 million for the year ended December 31, 2025, primarily due to lower cash and investment balances [450]. - Cash, cash equivalents, and marketable securities totaled $518.6 million as of December 31, 2025, sufficient to meet estimated working capital requirements through 2027 [464]. - The company anticipates further capital raising efforts over the next twelve months, including potential licensing of drug candidates and issuance of debt or equity [465]. - The company expects revenue to decrease over the next twelve months due to a decline in services under contract manufacturing and research agreements [444]. - Net cash used in operating activities increased to $210.9 million for the year ended December 31, 2025, up from $157.8 million in 2024, primarily due to increased R&D expenses [468]. - Net cash provided by investing activities was $209.1 million for the year ended December 31, 2025, compared to net cash used of $290.1 million in 2024, driven by net sales and maturities of marketable securities [471]. - Net cash provided by financing activities decreased to $2.4 million for the year ended December 31, 2025, down from $441.4 million in 2024, mainly due to reduced net proceeds from stock issuances [473]. - The company plans to incur significant costs in R&D, including preclinical and clinical trials, and anticipates milestone payments as drug candidates progress through clinical trials [470]. Safety and Efficacy - Barzolvolimab achieved a mean reduction in UAS7 of 82% at Week 12 for the 4.5 mg/kg Q8 group, compared to 67% for both the 3.0 mg/kg Q8 and 1.5 mg/kg Q4 groups [372]. - At Week 12, 67% of patients in the 4.5 mg/kg Q8 group achieved complete control (UAS7=0), while 43% maintained this at Week 24 [372]. - The study included 208 patients, with a primary endpoint of mean change in UAS7 from baseline to Week 12, showing statistically significant improvements across all dosing regimens compared to placebo [376]. - At Week 12, the LS mean change in UAS7 was -23.87 for the 300 mg Q8W group, -23.02 for the 150 mg Q4W group, and -17.06 for the 75 mg Q4W group, all significantly better than the -10.47 change in the placebo group [378]. - 71% of patients treated with barzolvolimab 150 mg Q4W and 52% of those treated with 300 mg Q8W had a complete response (UAS7=0) at Week 52 [384]. - At Week 52, 86% mean reduction in angioedema activity was reported for the 150 mg Q4W arm, and 82% for the 300 mg Q8W arm [383]. - 72% of patients had angioedema at baseline, with significant improvements in AAS7 observed across all doses at Week 12 [381]. - Barzolvolimab was well tolerated, with most adverse events being mild to moderate; common events included hair color changes (9%) and neutropenia (8%) without a clear association with infections [374]. - Up to 82% of patients reported that CSU symptoms no longer impacted their quality of life at Week 52, with 95% reporting meaningful improvement based on DLQI [384]. - Long-term follow-up data indicated sustained clinical benefits, with patients continuing to experience improvements seven months after treatment completion [385]. - At Week 76, UAS7 mean change from baseline was -20.42 for 150 mg Q4W and -21.10 for 300 mg Q8W, with 41% and 35% of patients achieving complete response respectively [388]. - 56% of patients on 150 mg Q4W and 47% on 300 mg Q8W had well-controlled disease (UAS7≤6) at Week 76 [388]. - In a Phase 1b trial, 95% of patients with ColdU and SD achieved a complete response at 3 mg/kg, with a median duration of complete response of 77+ days [392]. - Topline data from the Phase 2 study indicated a statistically significant difference in negative provocation tests compared to placebo at Week 12 [397]. - Barzolvolimab demonstrated a favorable safety profile with no new safety signals identified during the follow-up period [388]. - Long-term follow-up data showed that 10 out of 14 patients maintained complete control of their disease at Week 12 post-treatment [394]. - At Week 12, 46.9% and 53.1% of patients treated with barzolvolimab at 150 mg and 300 mg respectively achieved a negative provocation test for Cold Urticaria, compared to 12.5% in the placebo group, with p-values of 0.0023 and 0.0011 [398]. - For Symptomatic Dermographism, 57.6% and 42.4% of patients at 150 mg and 300 mg achieved a complete response, compared to 3.2% in the placebo group, with p-values of <0.0001 and 0.0003 [398]. - By Week 20, up to 66% of Cold Urticaria patients and 49% of Symptomatic Dermographism patients achieved a complete response, compared to 16% and 10% in the placebo group respectively [401]. - Barzolvolimab demonstrated a favorable safety profile, with 18% of patients experiencing hair color changes and 12% experiencing neutropenia, both of which were mostly grade 1 adverse events [399]. - In a Phase 1b study for Prurigo Nodularis, 57% of patients receiving a single IV dose of 3.0 mg/kg barzolvolimab achieved a ≥4-point decrease in WI-NRS by Week 8, compared to 25% in the placebo group [407]. Manufacturing and Regulatory - Barzolvolimab's manufacturing process has been successfully scaled up for late-stage trials, with pre-filled syringes completed and in use for Phase 3 trials [417]. - The company recorded a fair value of contingent consideration at $0.0 million as of December 31, 2025, related to the acquisition of Kolltan [426]. - Revenue recognition is based on the completion of performance obligations, with significant estimates involved in clinical trial costs and regulatory approvals [428]. - Research and development expenses primarily consist of clinical trial costs, manufacturing of clinical material, and personnel costs [437]. - Stock-based compensation expense is recognized using the straight-line method over the vesting term, relying on estimates of future events [439].

Financial Performance - Total revenue for Q4 2025 was $0.1 million, and $1.5 million for the year, compared to $1.2 million and $7.0 million in 2024, reflecting a decrease primarily due to reduced services under manufacturing and R&D agreements [12]. - Net loss for Q4 2025 was $81.3 million, or ($1.22) per share, and $258.8 million, or ($3.90) per share for the year, compared to a net loss of $47.1 million, or ($0.71) per share in Q4 2024 [17]. Research and Development - Research and development expenses increased to $75.3 million in Q4 2025 and $245.1 million for the year, compared to $46.9 million and $163.6 million in 2024, driven by higher clinical trial and manufacturing costs [15]. - Enrollment in the Phase 3 chronic spontaneous urticaria (CSU) studies was completed six months ahead of schedule, with 1,939 patients enrolled across 43 countries and over 500 sites [7]. - Topline data from the Phase 3 CSU studies is expected in Q4 2026, supporting a planned BLA filing in 2027 [6]. - The company initiated a global Phase 3 study in cold urticaria and symptomatic dermographism in December 2025, with barzolvolimab being the first drug to show clinical benefit in these conditions [7]. - Topline data from Phase 2 studies in prurigo nodularis and atopic dermatitis are expected in 2026, with enrollment completed in both studies [13]. - The company anticipates multiple important data readouts across its pipeline in 2026, including data from the novel bispecific program CDX-622 [3]. Cash and Liabilities - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $518.6 million, down from $583.2 million as of September 30, 2025, primarily due to cash used in operating activities [11]. - Current liabilities increased to $50,991 million from $39,501 million, reflecting a growth of approximately 29% [26]. - Long-term liabilities decreased to $4,827 million from $5,834 million, showing a reduction of about 17% [26]. - Stockholders' equity decreased to $527,165 million from $747,005 million, indicating a decline of approximately 29.4% [26]. - Total liabilities and stockholders' equity decreased to $582,983 million from $792,340 million, representing a decrease of about 26.4% [26]. Cash Position - Celldex believes its cash position is sufficient to meet estimated working capital requirements and fund operations through 2027 [18].

Core Insights - Celldex reported strong enthusiasm for its drug barzolvolimab, highlighting its efficacy across multiple indications and the completion of enrollment in Phase 3 studies ahead of schedule [2][5][6] - The company anticipates significant data readouts in 2026, including topline data from Phase 3 studies in chronic spontaneous urticaria (CSU) and additional studies in prurigo nodularis and atopic dermatitis [2][5][10] - Celldex is preparing for a Biologics License Application (BLA) filing for barzolvolimab in CSU, which could position the company as a leader in immunology [2][5] Recent Program Highlights - Barzolvolimab is a humanized monoclonal antibody targeting mast cells, crucial for inflammatory responses in conditions like chronic urticarias [3] - Enrollment in Phase 3 CSU studies (EMBARQ-CSU1 and EMBARQ-CSU2) was completed with 1,939 patients across 43 countries, making it the largest program for antihistamine refractory CSU [5][6] - The Phase 3 studies aim to establish the efficacy and safety of barzolvolimab in adult patients who remain symptomatic despite existing treatments, with topline data expected in Q4 2026 [5][6] Financial Highlights - As of December 31, 2025, Celldex had cash, cash equivalents, and marketable securities totaling $518.6 million, down from $583.2 million at the end of Q3 2025, primarily due to increased operating expenses [10][11] - Total revenue for Q4 2025 was $0.1 million, with annual revenue of $1.5 million, a decrease from $1.2 million and $7.0 million in the same periods of 2024 [11] - Research and development expenses rose to $75.3 million in Q4 2025 and $245.1 million for the year, reflecting increased clinical trial costs and employee headcount [12][14] Future Guidance - Celldex expects its current cash position to be sufficient to meet working capital needs and fund operations through 2027 [17] - The company is set for a landmark year in 2026 with multiple clinical readouts and data presentations planned [5][10]

Core Insights - Celldex has completed enrollment in its global Phase 3 program for barzolvolimab in chronic spontaneous urticaria (CSU), consisting of two trials with a total of 1,939 patients, marking it as the largest program for antihistamine refractory CSU [1][2][3] - The completion of enrollment six months ahead of schedule underscores the significant unmet need for effective treatments in CSU, with topline results expected later in 2026 and a BLA submission planned for 2027 [2][6] Study Design and Objectives - The Phase 3 program aims to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment, involving randomized, double-blind, placebo-controlled trials [3] - Patients were randomized to receive either barzolvolimab 150 mg every 4 weeks, 300 mg every 8 weeks, or placebo for 52 weeks, with the primary endpoint focusing on reducing urticaria activity at Week 12 [3] Clinical Efficacy - Barzolvolimab targets mast cells, potentially transforming the treatment landscape for CSU by providing rapid and durable efficacy, with up to 51% of patients achieving complete response at 12 weeks, increasing to 71% at 52 weeks [2][5] - Significant improvements were reported in angioedema control and quality of life, with up to 65% of patients being angioedema-free at 12 weeks, rising to 77% at Week 52 [2][5] Patient Impact - CSU is characterized by spontaneous hives and angioedema, leading to a substantial mental health burden and a 1.7-fold increase in all-cause mortality over five years, highlighting the critical need for effective treatments [8] - The goal of CSU treatment is complete symptom absence, yet many patients continue to experience significant distress despite current therapies [8] Future Directions - Barzolvolimab is being studied not only in CSU but also in other conditions such as cold urticaria and symptomatic dermographism, with additional indications planned for the future [7] - A global Phase 3b long-term extension study is ongoing, allowing patients to continue treatment after the Phase 3 trials [3]

Core Insights - Celldex announced multiple presentations of Phase 2 clinical trials for barzolvolimab at the 2026 AAAAI Annual Meeting, focusing on chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) [1][2] Group 1: Clinical Trial Presentations - New data from the Phase 2 ColdU and SD Open Label Extension (OLE) will be presented, indicating that retreatment with barzolvolimab results in rapid improvement in urticaria control after symptom recurrence [2] - The presentations include: - **Phase 2 ColdU and SD Study**: "Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria" on February 27, 2026 [2] - **Phase 2 CSU Study**: "Prolonged Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria" on February 27, 2026 [2] - **Phase 2 ColdU and SD Study**: "Retreatment with Barzolvolimab Leads to Rapid Improvement in Urticaria Control After Symptom Recurrence in Chronic Inducible Urticaria" on March 1, 2026 [2] Group 2: Barzolvolimab Overview - Barzolvolimab is a humanized monoclonal antibody with a novel mechanism of action targeting mast cells by binding to a unique part of the KIT receptor, which is critical for mast cell function and survival [3] - The drug shows significant potential as a first-in-class treatment for CSU, ColdU, and SD, based on data from robust Phase 2 studies [3] - Barzolvolimab is currently undergoing Phase 3 studies for CSU and ColdU/SD, as well as Phase 2 studies for prurigo nodularis (PN) and atopic dermatitis (AD) [3] Group 3: Company Background - Celldex is focused on pioneering new therapies in immunology, particularly antibody-based treatments that engage the human immune system to address allergic, inflammatory, and autoimmune disorders [4]

Company Project Progress - Barzol drug Phase III clinical trial is expected to complete patient enrollment by July 2026, which is considered the most important event of the year by management. The company also plans to initiate evaluations for new indications such as food allergies and allergic rhinitis [1] - The company plans to announce Phase II clinical trial results for nodular prurigo and atopic dermatitis in 2026, which will be used to determine the dosing regimen for subsequent registration studies [1] - Updates on the bispecific project CDX622 are expected in the third quarter of 2026, with results from a subcutaneous single-dose escalation study also planned for release within the year. Based on these data, the company intends to initiate mechanism validation studies for severe asthma [1] Strategic Advancement - The company is focused on validating its bispecific platform (CDX622) and promoting Barzol as the preferred drug in the field of CSU and other diseases. For commercialization, the company plans to independently advance in the U.S. market while considering partnerships for markets outside the U.S. [2] Institutional Perspectives - On January 7, 2026, Celldex Therapeutics' stock price surged by 5.18%, with 80% of brokerage firms giving a buy recommendation. However, it is important to note that the company is still in the research and development phase, with the latest financial report showing zero revenue and a negative net profit [3]